Alzheimer's Drugs: Meaningless Benefit, High Risk?

A recent review has concluded that drugs designed to slow Alzheimer's disease progression provide no significant benefit to patients and may elevate the risk of brain swelling and bleeding. Researchers stated the observed effects on individuals with early-stage Alzheimer's and dementia were "either absent or consistently small," falling far below what is clinically noticeable.

However, this assessment has been met with sharp criticism from charities. They argue that the review's authors inappropriately grouped results from both unsuccessful and successful drug trials, thereby painting an entire class of medications with the same broad, negative brush. This approach risks obscuring potential benefits of certain treatments.

Anti-amyloid medicines, including lecanemab and donanemab (licensed in the UK but not approved for NHS use due to cost-effectiveness concerns), aim to clear protein deposits in the brain to slow cognitive decline. The review analyzed 17 studies involving over 20,000 patients, finding effects on cognitive function and dementia severity to be "trivial" after 18 months.

Critics also point out that 18 months is a relatively short period for a slowly progressing condition like Alzheimer's, and that drugs may be used longer in clinical practice. The review's methodology of combining various discontinued and experimental drugs with newer ones has also been questioned for inevitably leading to a conclusion of clinical ineffectiveness as a group.

Despite these criticisms, the review highlights concerns about side effects like brain swelling and bleeding, though these were asymptomatic for most patients in the studies. The debate underscores the complexity of Alzheimer's treatment and the ongoing need for nuanced interpretation of research findings.